How Robots Are Introducing A New Dimension To Healthcare Service Delivery

Gastroenterology

Precigen’s PRGN-3006; Yescarta Approved a...

FDA Approves Yescarta as a First CAR T-cell Therapy for Initial Treatment of R/R Large B-cell Lymphoma Until now, existing CAR-T therapies have been reserved for patients with blood cancer who have...

Apr 05, 2022

pharma-news-for-sandoz-agios-organon-bms-sanofi-bayer-lilly
Sandoz’s Generic Revlimid; Agios’ Pyrukynd; Organon Announces 4Q & Full-year Earnings Report; BMS’ CAR-T Drug Breyanzi; Sanofi & Regeneron’s Dupixent Trial; AZ & Daiichi’s Drug Enhertu; Bayer’s Drug Kerendia; Lilly Releases Mirikizumab Data

Sandoz Launches generic Revlimid in 19 European Countries, Bringing a Flood of Competition to BMS' Megablockbuster Since Bristol Myers Squibb acquired Celgene and its megablockbuster Revlimid, the company has been bracing for the day when the multiple myeloma superstar would face generic competition. Sandoz, a s...

Find More
medtech-news-for-stryker-genesis-ambu-biocardia-abbott-atheart
Stryker’s Tornier Shoulder Arthroplasty; Genesis Acquires JC Medical; FDA Clearance to Single-Use Gastroscope; BioCardia’s CardiAMP Cell Therapy System; Abbott’s Dual-Chamber Leadless Pacemaker; atHeart’s ASCENT ASD U.S. IDE

BioCardia Receives FDA Breakthrough Device Designation for CardiAMP Cell Therapy System for Heart Failure On February 03, 2022, The US Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the CardiAMP® Cell Therapy System for the treatment of heart failure, according to BioCardia®, ...

Find More
pharma-news-for-pfizer-takeda-novartis-roche
Pfizer to acquire Arena Pharma; Takeda’s ‘Wave 2’ multiple myeloma med data; Novartis’s next-gen CAR-Ts clinical data; Roche unveils Avenio system

Pfizer acquires drugmaker Arena for USD 6.7 billion to address unmet needs Pfizer declared that it is acquiring Arena Pharmaceuticals, a drug company specializing in inflammation and immunology, for almost USD 7 billion. The pharma giant said it would finance the agreement, worth USD 6.7 billion, with cash on ha...

Find More

More Views & Analysis

pharma-news-for-astrazeneca-wision-getinge-lumithera
AstraZeneca-Moderna’s AZD8601 VEGF-A mRNA Trial; Wision AI gets CE Mark approval; Getinge acquires Verrix; LumiThera buys Diopsys

AstraZeneca, Moderna announces positive data of mRNA potential in heart failure patients  Moderna, Inc., a biotechnology company is pioneering messenger RNA (mRNA) therapeutics and vaccines, declared positive data from the AstraZeneca-led Phase 2 (EPICCURE) study assessing the use of an mRNA therapeutic, wh...

Find More

recent-pharma-biotech-news-for-prolacta-renovia-magnus-hinge-health
Magnus Medical’s tech gets breakthrough status; Prolacta develops tests for pathogens detection; Renovia gets breakthrough designation for leva system; Hinge Health secures $600M funding

Magnus Medical’s neurostimulation technology gets FDA breakthrough status to treat MDD Magnus Medical has secured a breakthrough device designation from the US Food and Drug Administration (FDA) for its neurostimulation technology for major depressive disorder (MDD) treatment. The individualised, rapid-acting...

Find More

recent-pharma-news-for-biogen-phathom-vertex-natera
Biogen’s ALS drug Tofersen (BIIB067); Phathom’s erosive esophagitis drug trial; Vertex’s islet cell therapy; Natera launches lung DNA test

Biogen’s tofersen fails to meet the primary goal in the Phase III ALS trial Biogen has announced that its investigational antisense drug, tofersen (BIIB067), flunked to meet the primary goal of Phase III VALOR clinical trial in superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS) patients. Althou...

Find More

Probiotics Market
Analyzing the Emerging Demand for the Probiotics

Probiotics are a type of beneficial or live bacteria that provides various valuable benefits such as boosting the immune system and maintaining digestive health. Due to their beneficial properties, the demand is growing at a significant rate. Probiotics are available as dietary supplements. In the food supplemen...

Find More

pharma-news-and-updates-for-nanox-takeda-visus-lqt-therapeutics
LQTT secures $19M; Nanox acquires Zebra Medical Vision; Takeda leads IBD drug; Visus raises $20M

LQT Therapeutics secures USD 19 Million to tackle heart diseases with Sanofi compounds LQT Therapeutics intends to tackle debilitating heart arrhythmias with limited interventions, and investors are planting a seed in the biotech's heart with USD 19 million.  The two-year-old Canadian biotech will utiliz...

Find More

Crohns-Disease-Market
Novel Therapies form the Nucleus of the Growth in the Crohn’s Disease Therapeutic Market

Crohn's disease is one of the most prevalent types of Inflammatory bowel diseases characterized by abdominal pain and diarrhea, with patients often experiencing weight loss and perianal disease. Based on the location of the body, Crohn's disease affects the disease can be of different types, including ileocolitis, ...

Find More

The medical device industry is a dynamic, innovative, and heterogeneous sector. The MedTech industry.....

Find More

Gastroesophageal Reflux Disease (GERD, also known as chronic acid reflux) is a digestive disorder in.....

Find More

Cystic fibrosis (CF) is a hereditary condition leading to chronic lung infections and eventually dec.....

Find More

Cell therapies now are often recommended to treat cancer in several ways, out of which CAR T-cell th.....

Find More

Diabetic macular edema (DME) is an eye disease in which there is fluid buildup in the macula. Even t.....

Find More

Pulmonary Arterial Hypertension (PAH) is a rare, chronic, and progressive form of Pulmonary Hyperten.....

Find More